Welcome to our dedicated page for Entera Bio Ltd. SEC filings (Ticker: ENTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Entera Bio Ltd. filings document a Nasdaq-listed Israeli clinical-stage biopharmaceutical company developing oral peptide and protein replacement therapies. Its recent Form 8-K disclosures cover financial results, Regulation FD updates, EB613 regulatory and clinical-development communications, and business updates across oral peptide programs.
The filing record also documents material agreements and capital structure matters, including collaboration and license arrangements with OPKO, a private placement involving ordinary shares, pre-funded warrants and ordinary share warrants, and governance disclosures related to board appointments. These filings frame ENTX's operating updates, securities structure, partnership obligations and public-company governance.
Entera Bio Ltd. held its 2026 Annual Meeting of Shareholders on July 14, 2026. Shareholders approved an amendment to the 2018 Equity Incentive Plan adding a one-time 2,500,000 Ordinary Shares to the pool available for equity awards. They also approved an Articles Amendment increasing authorized Ordinary Shares from 140,010,000 to 350,000,000.
Shareholders re-elected Sean Ellis, Steven D. Rubin and Geno H. Germano as Class III directors for terms running until the 2029 Annual Meeting. They approved revised non-executive director compensation, several one-time and share-based compensation grants, an advisory say-on-pay proposal, and the appointment of Kesselman & Kesselman as independent auditors for the fiscal year ending December 31, 2026.
Toledano Miranda Jayne reported acquisition or exercise transactions in this Form 4 filing.
Entera Bio Ltd. reported that CEO Toledano Miranda Jayne received two grants of stock-settled restricted stock units representing 72,993 and 347,567 ordinary shares on July 14, 2026. The awards were approved by the board on May 7, 2026 and by shareholders on July 14, 2026.
One grant was awarded in lieu of her 2025 annual cash bonus, and the other in lieu of $100,000 of her 2026 base salary. Both RSU grants vest ratably on a quarterly basis over a one-year period that began on May 1, 2026, with full acceleration upon a Change in Control under the company’s 2018 Equity Incentive Plan.
Entera Bio Ltd. has called its 2026 Annual Meeting of Shareholders for July 14, 2026 in Jerusalem. Shareholders of record as of May 19, 2026, when 49,290,234 ordinary shares were outstanding, may vote in person, by mail or via Internet under SEC “Notice and Access” rules.
Key votes include electing three Class III directors to terms ending in 2029, multiple director and executive compensation items, and an amendment to the 2018 Equity Incentive Plan to increase the number of shares issuable thereunder by 2,500,000 shares. Shareholders will also vote on increasing the Company’s authorized share capital, an advisory say‑on‑pay resolution, and ratification of Kesselman & Kesselman (PwC affiliate) as independent auditors for 2026.
The proxy details Israeli Companies Law requirements, including special majority provisions for certain compensation proposals and definitions of controlling shareholders and personal interests, and describes Entera Bio’s board structure, committee composition, corporate governance practices and major shareholders.
Entera Bio Ltd. registers for resale up to 19,569,472 ordinary shares comprised of 2,425,000 issued shares, up to 5,402,789 issuable upon exercise of Pre‑Funded Warrants and up to 11,741,683 issuable upon exercise of Ordinary Share Warrants from a Private Placement consummated on April 2, 2026. The resale registration is being made pursuant to a Registration Rights Agreement and the company will not receive proceeds from resale transactions; however, it may receive proceeds from any cash exercises of the Warrants. The prospectus states the company will pay registration fees and expenses and that offer methods and underwriter names, if any, will be specified in prospectus supplements.
Entera Bio Ltd. is soliciting proxies for its 2026 Annual Meeting of Shareholders to be held July 14, 2026, where shareholders will vote on ten proposals including the election of three Class III directors and amendments to its equity plans and authorized share capital.
The record date for voting is May 19, 2026. The meeting packet includes the Company’s audited consolidated financial statements for the year ended December 31, 2025, and the Proxy Materials are being furnished under the SEC "Notice and Access" model.
Galitzer Hillel reported acquisition or exercise transactions in this Form 4 filing.
Entera Bio Ltd. reported that Chief Operating Officer Hillel Galitzer received a grant of 72,993 stock-settled restricted stock units at a stated price of $0.0000 per ordinary share. The Board approved the award on May 7, 2026 in lieu of a cash bonus he was otherwise entitled to. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on May 1, 2026. Following this equity award, Galitzer directly holds 163,566 ordinary shares of Entera Bio.
Yaacov-Garbeli Dana reported acquisition or exercise transactions in this Form 4 filing.
Entera Bio Ltd. granted 58,394 stock-settled restricted stock units tied to its ordinary shares to A2Z Counseling Ltd., an entity associated with Chief Financial Officer Dana Yaacov-Garbeli, as compensation in lieu of a cash bonus. The units vest quarterly over a one-year period that began on May 1, 2026.
Following this award, A2Z Counseling Ltd. held 171,441 ordinary shares indirectly for the reporting person, who owns a 33.33% interest in the entity and has effective voting and disposition control, while disclaiming beneficial ownership beyond any pecuniary interest.
Burshtein Gregory reported acquisition or exercise transactions in this Form 4 filing.
Entera Bio Ltd. reported that its Chief of R&D, Gregory Burshtein, received an equity grant rather than cash. He was awarded 87,591 ordinary shares in the form of stock-settled restricted stock units, approved by the Board on May 7, 2026, in lieu of a cash bonus.
The restricted stock units vest ratably on a quarterly basis over one year, beginning May 1, 2026. After this grant, Burshtein directly owns 189,033 ordinary shares, reflecting routine, compensation-related equity that does not involve any open-market buying or selling.